Blinatumomab to prevent return of B-cell leukemia after transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests if blinatumomab, an immunotherapy drug, can prevent B-cell acute lymphoblastic leukemia (B-ALL) from coming back in people who have already had a donor stem cell transplant. You may qualify if you had a relapse before transplant or had a positive minimal residual disease test, and if you are now in complete remission after the transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B-ALL and either relapsed before transplant or had a positive test for a small number of leukemia cells in your bone marrow just before transplant
- You are between 16 and 65 years old
- Your overall health is good (able to care for yourself or up and about more than half the day)
- You are in complete remission (no signs of leukemia) after your donor stem cell transplant
- Your blood cell counts have recovered enough after transplant (for example, your white blood cells and platelets are at safe levels without needing daily growth factor shots or platelet transfusions)
- You do not have active graft-versus-host disease (a condition where the donor cells attack your body), active infections, or serious organ problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a short course of blinatumomab (a targeted immunotherapy) given before a stem cell transplant in people with low amounts of B-ALL leukemia. The goal is to prepare the body for transplant and improve outcomes.
This trial tests if a targeted drug, blinatumomab, can help prevent leukemia from coming back after a stem cell transplant. It is for people with high-risk B-cell acute lymphoblastic leukemia who have achieved remission but are at high risk of relapse.
This trial tests a drug called blinatumomab for people with B-ALL whose leukemia has come back at a very low level (detected only by sensitive testing) after a stem cell transplant. The goal is to see if blinatumomab can clear these remaining leukemia cells and prevent a full relapse.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
This trial tests the drug blinatumomab for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after a stem cell transplant. The goal is to see if blinatumomab can safely treat the relapse.
Hear when a new Leukemia, Lymphoid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.